News
3 Reasons Behind Exelixis Stock's Big Bounce
After experiencing a dismal September and sliding quite a bit over the last few weeks after a rebound, Exelixis (NASDAQ: EXEL) stock enjoyed a big bounce on Thursday. The biotech announced its....
3 Reasons It's Smart to Buy Celgene's Stock Now
Celgene Corp. (NASDAQ: CELG) shares nose-dived in October following a trial failure and third-quarter financials that failed to impress. However, there are good reasons investors ought to consider....
The Precision Medicine Stock That's Revolutionizing Cancer Treatment
Foundation Medicine's (NASDAQ: FMI) genetic screening tests are leading the way in discovering what medicines will work best in cancer patients based on their DNA. As more specialized drugs....
The Single Biggest Reason Teva Pharmaceutical Industries Imploded and Fell 22% in October
Shares of Teva Pharmaceutical Industries (NYSE: TEVA), a developer of branded and generic drugs and the largest generic drugmaker in the world, tumbled another 22% in October, according to data....
Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today
Shares of clinical-stage biopharma Idera Pharmaceuticals (NASDAQ: IDRA) jumped over 11% today without any company-specific news. Why? The two leading RNA-based genetic medicine companies were....
Here's Why bluebird bio Inc. Is Surging Again Today
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, are on the move for the second day in a row. Yesterday, the stock jumped in response to a....
The Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10%
Shares of Exelixis (NASDAQ: EXEL), a mid-cap drug developer with a focus on novel cancer therapies, rocketed higher by as much as 10% during Thursday's trading session after the company reported....
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company....
Why Juno Therapeutics Shares Are Going Up 21.2% Today
After the company released its third-quarter progress report and shared the latest data from its lead drug, JCAR017, shares of Juno Therapeutics (NASDAQ: JUNO) are shooting 21.2% higher at 2:30....
Here's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today
As of 1:18 p.m. EDT on Thursday, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) are up 13.7%, while shares of its biotech peer Ionis Pharmaceuticals Inc. (NASDAQ: IONS) are down....
Why Teva Pharmaceutical Is Crashing Today
After the company provided investors with yet another disappointing update to its financial performance, shares in Teva Pharmaceutical (NYSE: TEVA) are losing 15% as of 1 p.m. EDT.It's been tough....
Here's Why Intellia Therapeutics Sank as Much as 17.7% Today
Shares of CRISPR gene-editing biopharma Intellia Therapeutics (NASDAQ: NTLA) dropped nearly 18% today after the company announced a major public share offering to increase its cash balance. The....
Here's Why Neurocrine Biosciences Is Soaring
In response to the company reporting better-than-expected quarterly results, shares of Neurocrine Biosciences (NASDAQ: NBIX), a commercial stage biotech focused on neurological and endocrine....
Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis
It's a great time to be a biotech focused on CAR-T (chimeric antigen receptor T-cell therapy). Juno Therapeutics (NASDAQ: JUNO) stock has soared so far in 2017, partially due to its own good....
5 Things Pfizer's Management Just Said That You Don't Want to Miss
Forget Pfizer's (NYSE: PFE) third-quarter earnings announcement. The real story lies in what the company's top executives said afterward.The big pharma company reported its third-quarter results....
Why ImmunoGen, Inc. Got Burned into ASH Today
ImmunoGen (NASDAQ: IMGN) closed down 12.6% on Wednesday, following the release of abstracts for the American Society of Hematology (ASH) meeting next month.The data covers a pair of ImmunoGen's....
Here's Why It's Oca-Liftoff for Intercept Pharmaceuticals Inc.
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT), a small-cap biotech company focused on the development of drugs to treat an assortment of liver diseases, vaulted higher by as much as 10% on....
BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal
It was a solid third quarter for BioMarin Pharmaceutical (NASDAQ: BMRN) as the biotech keeps plugging along, increasing sales of its orphan drugs while making progress on its pipeline drug....
What's Causing Adamas Pharmaceuticals to Spike Higher Today
After a leading hedge fund reported it bought shares last month and in the wake of industry watcher upgrades, shares in Adamas Pharmaceuticals (NASDAQ: ADMS) rallied more than 10% higher earlier....
Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Pfizer Inc. (NYSE: PFE)Q3 2017 Earnings Conference CallOct. 31, 2017, 8:00 a.m. EDTOperatorContinue readingSource: Fool.com
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially....
Why bluebird bio Inc. Jumped Higher Today
Shares of biotech bluebird bio (NASDAQ: BLUE) are up 7.3% at 12:24 p.m. EDT, having been up as much as 16.3% today, after the company disclosed data in its abstracts for the American Society of....
3 Worst Performing Stocks in October
Halloween has come and gone, but some stocks have been more tricks than treats. As good as October may have been for a lot of investors, some stocks got totally crushed last month.Trivago (NASDAQ:....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
Up in Smoke: This Marijuana Stock Imploded Last Week
Few industries have put a wider smile on investors' faces this year than marijuana. As recently as June, the average marijuana stock was higher by more than 330% over the trailing 12-month period,....